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Multiple system atrophy (MSA) is a progressive neurodegenerative disease presenting clinically with parkinsonian, cerebellar,
and autonomic features. a-Synuclein (asyn), encoded by the gene SNCA, is the main constituent of glial cytoplasmic inclusion
(GCI) found in oligodendrocytes in MSA, but the methods of its accumulation have not been established. The aim of this
study is to investigate alterations in regional and cellular SNCA mRNA expression in MSA as a possible substrate for GCI for-
mation. Quantitative reverse transcription polymerase chain reaction (qPCR) was performed on postmortem brain samples
from 15 MSA, 5 IPD, and 5 control cases to investigate regional expression in the frontal and occipital regions, dorsal puta-
men, pontine base, and cerebellum. For cellular expression analysis, neurons and oligodendrocytes were isolated by laser-
capture microdissection from five MSA and five control cases. SNCA mRNA expression was not significantly different between
the MSA, IPD and control cases in all regions (multilevel model, P 5 0.14). After adjusting for group effect, the highest
expression was found in the occipital cortex while the lowest was in the putamen (multilevel model, P < 0.0001). At the cellu-
lar level, MSA oligodendrocytes expressed more SNCA than control oligodendrocytes and expression in MSA neurons was
slightly lower than that in controls, however, these results did not reach statistical significance. We have demonstrated
regional variations in SNCA expression, which is higher in cortical than subcortical regions. This study is the first to demon-
strate SNCA mRNA expression by oligodendrocytes in human postmortem tissue using qPCR and, although not statistically
significant, could suggest that this may be increased in MSA compared to controls.
GLIA 2014;62:964–970
Key words: a-synuclein, multiple system atrophy, oligodendrocytes, glial cytoplasmic inclusions, laser-capture microdissection
Introduction
Multiple system atrophy (MSA) is a progressive neurode-generative disease that clinically presents with parkinso-
nian, cerebellar and autonomic features and pathologically
with glial cytoplasmic inclusions (GCIs) found in oligoden-
drocytes, myelin damage, neuronal loss, and gliosis (Ahmed
et al. 2012; Ubhi et al. 2011). The main constituent of GCIs
is a-synuclein (asyn), as such, classifying MSA as part of the
a-synucleinopathy group of diseases, which also includes Par-
kinson’s disease (PD) and dementia with Lewy bodies (DLB).
MSA is pathologically subtyped into striatonigral (SND), oli-
vopontocerebellar (OPC) or mixed type reflecting the pre-
dominance of pathological burden in the respective
anatomical structures. However, the basis for this regional
vulnerability is poorly understood (Jellinger et al. 2005;
Ozawa et al. 2004). The mechanism by which asyn accumu-
lates in oligodendrocytes as GCIs is as yet unknown but is
hypothesized to result from the uptake of asyn, released from
neurons, by oligodendrocytes or by overexpression of SNCA
mRNA in the disease condition (Reyes et al. 2014; Ubhi
et al. 2011). Mutations and multiplications in SNCA, the
gene encoding asyn, have been identified in some cases of
familial PD and these have occasionally been found to have
oligodendroglial inclusions resembling GCIs (Gwinn-Hardy
et al. 2000; Kiely et al. 2013; Markopoulou et al. 2008; Obi
et al. 2008). Despite this, no mutations in SNCA have been
associated with MSA (Gwinn-Hardy et al. 2000; Kiely et al.
2013; Markopoulou et al. 2008; Obi et al. 2008). There are
limited studies in the literature of SNCA expression in MSA.
In a small case study, SNCA mRNA levels in cortical regions
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(frontal, temporal, or occipital) of MSA brains did not differ
from those in controls using quantitative PCR (qPCR)
(Ozawa et al. 2001). Cortical regions are less severely affected
by GCI pathology and neuronal loss in MSA and this may
explain these results. Based on findings of our study, it may
be plausible to suggest that expression differences are more
likely to arise in areas more severely affected in MSA such as
the pons and cerebellum. However, there are conflicting data
with regards to SNCA expression in the pons. Jin et al.
(2008) observed no difference in SNCA copy number and
mRNA expression in the pons of MSA and control cases,
while down-regulation was reported by Langerveld et al.
(2007). Different isoforms of SNCA resulting from alternative
mRNA splicing were investigated in PD, DLB, and MSA and
isoform SNCA 98 was found to be up-regulated in the frontal
cortex of MSA, while there was no significant difference in
the level of SNCA 126 (Beyer et al. 2008).
Previous studies focused on understanding SNCA
mRNA expression in MSA at the regional level and there is
little information relating to cellular expression. In situ
hybridization studies of SNCA mRNA expression in PD and
control cases have successfully identified expression in neurons
but not in oligodendrocytes (Jin et al. 2008; Kingsbury et al.
2004; Miller et al. 2005; Solano et al. 2000). Unravelling the
cellular expression profile of SNCA in MSA will help to shed
light on the possible contribution of overexpression in oligo-
dendrocytes as a mechanism for GCI formation. Therefore,
the aim of this study was to investigate the regional and cellu-
lar expression profile of SNCA in MSA subtypes and controls
using qPCR.
Materials and Methods
Tissue Collection
Samples were obtained from brains donated to the Queen Square
Brain Bank (QSBB) for Neurological Disorders, Department of
Molecular Neuroscience, UCL Institute of Neurology, London. The
donations were made according to ethically approved protocols, and
tissue is stored under a license issued by the Human Tissue Author-
ity (No. 12198). One half of the brain is sliced in the coronal plane,
flash frozen, and stored at 280C on arrival to the QSBB, while the
other half is fixed in 10% buffered formalin. Tissue was sampled
from the frozen half brain.
Case Selection
MSA cases were pathologically typed based on published criteria
into mixed, SND and OPCA subtypes (Ozawa et al. 2004). Five
MSA-SND, five MSA-OPCA, five MSA-mixed subtypes were
selected and sex and age matched to five IPD and four normal con-
trol cases to study regional asyn mRNA expression (Table 1). For
cellular mRNA expression, five MSA-mixed subtype and six neuro-
logically normal controls were used to isolate neurons and oligoden-
drocytes (Table 2).
Regional Sampling, RNA Extraction, and Reverse
Transcription
Frozen tissue (100 mg) from the posterior frontal region (cortex
and subcortical white matter), occipital region (cortex and subcorti-
cal white matter), dorsal putamen, pontine base, and cerebellum
(white matter) was collected and homogenised using TissueRuptor
(Qiagen, Germany). RNA extraction was carried out using RNeasy
Mini Kit (Qiagen, Germany) and cDNA synthesized using Super-
ScriptV
R
VILOTM cDNA Synthesis Kit (Invitrogen, UK) according to
the manufacturer’s instructions.
Cellular Sampling, RNA Extraction, and Reverse
Transcription
Neurons from the pontine base (1,000 cells) and oligodendrocytes
from the cerebellar white matter (1,000 cells) were isolated in five
MSA and six control cases using the PixCell II laser-capture micro-
dissection (LCM) system (Arcturus Engineering, Mountain View,
CA). Neurons were identified using toluidine blue stain and oligo-
dendrocytes using a rapid immunohistochemistry (IHC) protocol as
previously described (Waller et al. 2012). Briefly, 7-mm frozen sec-
tion were collected on uncharged, sterile glass slides and warmed to
RT for 30 sec. The sections were then fixed in ice-cold acetone for 3
min and immunostained using oligodendrocyte-specific protein
(OSP) primary antibody (Abcam, UK, ab7474) and VECTASTAIN
Elite ABC kit (Vector labs, Burlingame, CA, PK-6101). Sections
were blocked with normal goat serum (2%) for 3 min then incu-
bated in OSP (1:10) for 3 min at RT. After a brief rinse with tris-
buffered saline (TBS), sections were incubated in 5% biotinylated
secondary antibody for 3 min at RT, then rinsed again with TBS.
The avidin–biotin complex solution was then added to the section
for 3 min at RT then rinsed off. DAB peroxidase substrate kit (Vec-
tor labs, Burlingame, CA, SK-4100) was used to visualize the reac-
tion by incubating section for 3 min at RT. The sections were rinsed
with TBS, dehydrated in graded alcohol (70, 95, 100, 100% for 1
min each), cleared in two changes of xylene and allowed to air dry
in an air-flow hood for an hour prior to LCM. This rapid IHC pro-
tocol was carried out under sterile conditions and using
diethylpyrocarbonate (DEPC)-treated water. RNA extraction of
LCM samples was carried out using the Arcturus PicoPure RNA iso-
lation kit (Applied Biosystems, UK, KIT0204) and cDNA synthe-
sized using SuperScriptV
R
VILOTM cDNA Synthesis Kit (Invitrogen,
UK) according to manufacturer’s instructions. RNA quality and con-
centration was then assessed using the Nanodrop and Agilent Bioa-
nalyser 2100. Maintenance of RNA quality was adequate as assessed
by the RIN of samples before and after LCM was carried out. Prior
to LCM, samples had a mean RIN of 4.7 (range 4.2–5.8) declining
to 2.6 (range 2.0–3.1) after LCM and this is in keeping with previ-
ous findings (Waller et al. 2012).
Quantitative PCR
qPCR was performed on Stratagene MX3000p (Agilent technologies,
CA) using 50-ng cDNA and Power SYBR Green Master Mix
(Applied Biosystems) according to the manufacturer’s instructions.
All primers were run at the following thermal profile: one cycle at
95C for 10 min followed by 40 cycles at 95C for 15 min and
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60C for 1 min. Three reference genes, UCB, TBP, and GAPDH,
were determined as appropriate to normalize regional expression data
using qBase plus software (Biogazelle, Belgium). Due to limited sam-
ple volume, one reference gene (UBC) was used to normalize LCM
expression data. Primers for the gene of interest (GOI), SNCA, were
designed in house while the reference genes were obtained from
RTprimerDB (Table 3).
Expression Analysis and Statistics
Standard curves were used to extrapolate expression value of each gene
in each region or cell. The GOI was then normalized to the geometric
mean of the reference genes as recommended by Vandesompele et al.
(2002). A multilevel statistical model was used for regional expression
analysis while the Mann–Whitney U test was used to analyze cellular
expression results with the significance levels set at P< 0.05.
Results
Regional SNCA mRNA expression was examined in the pos-
terior frontal region, occipital region, dorsal putamen, pon-
tine base, and cerebellar white matter of three MSA subtypes
(mixed, SND, and OPCA), IPD, and control cases (Fig. 1).
SNCA expression level was highest in IPD and lowest in
MSA-SND, however, data analysis using a multilevel statisti-
cal model showed that there was no statistically significant
difference between the different groups (multilevel statistical
model, P 5 0.14). After adjusting for group effect, the high-
est expression was found in the occipital cortex while the low-
est was in the putamen. The differences between regions were
found to be statistically significant (multilevel statistical
model, P < 0.0001).
TABLE 1: Demographics of Regional Expression Cohort
Case Age Sex Diagnosis MSA pathological type PMI (hr)
1 56 F MSA Mixed 28
2 62 M MSA Mixed 20
3 64 F MSA Mixed 52
4 66 M MSA Mixed 105
5 70 F MSA Mixed 65
6 50 F MSA SND 4
7 54 F MSA SND 47
8 58 F MSA SND 11
9 63 M MSA SND 27
10 72 M MSA SND 50
11 56 M MSA OPCA 37
12 60 F MSA OPCA 62
13 61 M MSA OPCA ND
14 64 M MSA OPCA 35
15 66 F MSA OPCA 74
16 61 F IPD NA 26
17 63 M IPD NA 37
18 65 M IPD NA 43
19 67 F IPD NA 108
20 70 M IPD NA 75
21 57 M Control NA 79
22 69 M Control NA ND
23 71 M Control NA 39
24 73 F Control NA 24
NA: not applicable; ND: not documented; PMI: post-mortem interval.
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Next SNCA expression in neurons and oligodendrocytes
isolated by laser capture was explored in the pontine base and
cerebellar white matter, respectively, as these regions are
affected in MSA. SNCA expression was detected in neurons
and oligodendrocytes of both MSA and control cases, with
the highest level of expression being found in MSA oligoden-
drocytes (Fig. 2A). The fold changes in mRNA expression
between the different cell types and groups were also calcu-
lated (Fig. 2B). Although none of the differences identified
reached statistical significance, there was a slight increase in
expression in MSA oligodendrocytes as compared to control
oligodendrocytes (fold change5 0.7, Mann–Whitney U test,
P 5 0.18). Expression in MSA neurons was slightly decreased
as compared to control neurons (fold change5 –0.4, Mann–
Whitney U test, P5 0.46). Comparing the different cell types
within the same groups revealed that control oligodendrocytes
express 0.3 more SNCA than control neurons (Mann–Whit-
ney U test, P 5 0.92). The greatest difference was seen
between MSA oligodendrocytes and neurons where expression
in MSA oligodendrocytes was 3.1 times higher than MSA
neurons (Mann–Whitney U test, P 5 0.16).
Discussion
aSyn has been localized in the brain to neuronal presynaptic
terminals and may play a role in neuronal plasticity, vesicular
transport, and membrane interaction (Iwai et al. 1995; Kahle
et al. 2000; Reynolds et al. 2011). There has been great inter-
est in the possible mechanisms by which asyn forms primarily
oligodendroglial inclusions in MSA since its identification as
the main constituent of the GCIs. Understanding the
expression pattern of SNCA in MSA at both regional and cel-
lular levels is essential to determine if changes in expression
play a role in MSA pathogenesis and whether this influences
regional vulnerability to disease. The regional expression anal-
ysis in this study now demonstrates that SNCA expression
level varies across different brain regions in control, MSA,
and IPD groups. The greatest expression is found in the occi-
pital grey matter and the lowest level in the putamen. How-
ever, SNCA mRNA expression is not significantly different
between the MSA subgroups, IPD and control cases in all
regions. The expression trend found in MSA and control
cases used in this study is similar to that documented in
expression databases such as UKBEC and Allen Brain Atlas,
which analyze gene expression in control human brains
(Hawrylycz et al. 2012; Trabzuni et al. 2011). The similarity
in trend, where SNCA is generally expressed more in cortical
regions than subcortical and cerebellar regions, has at least
two main implications. The first is that the vulnerability of
StrN and OPC regions is not associated with a higher base-
line expression of SNCA. It could be hypothesized that the
concentration of GCIs in specific regions is due to higher
expression levels of SNCA in normal conditions in those
regions that is exacerbated by disease. Our data do not sup-
port this hypothesis as SNCA mRNA levels are higher in cort-
ical than subcortical regions in both normal and disease cases,
while GCI pathology is greater in subcortical and hindbrain
structures such as the StrN and OPC regions in MSA. This
also indicates that the disease does not cause an alteration in
expression levels in areas of greater vulnerability. The absence
of a difference in SNCA expression levels between the differ-
ent MSA groups, IPD, and controls may imply that factors
TABLE 2: Demographics of Cellular Expression Cohort
Case Age Sex Diagnosis MSA pathological type PMI (hr) RIN before LCM RIN after LCM
1 50 M MSA Mixed 30 4.8 2.6
2 70 F MSA Mixed 65 5.8 ND
3 56 M MSA Mixed 75 4.7 ND
4 64 F MSA Mixed 99 4.4 2.8
5 64 M MSA Mixed 100 5.1 3.1
6 69 M Control NA ND 4.4 ND
7 82 F Control NA ND 4.8 3.6
8 73 F Control NA 24 5.3 2.0
9 85 M Control NA 78 4.2 2.2
10 80 F Control NA 49 3.9 2.5
11 83 M Control NA 63 4.2 2.3
NA: not applicable; ND: not documented; PMI: post-mortem interval.
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contributing to pathogenic mechanisms of MSA may be fur-
ther downstream and not at the transcriptional level and
could suggest that impaired asyn degradation may contribute
to the disease. Another possibility is that any differences at
the transcriptional level are masked by the cellular heteroge-
neity of the samples. To overcome this problem, we used
LCM to obtain samples highly enriched in neurons and
oligodendrocytes.
It has long been suggested that mature oligodendrocytes
lack asyn (Jin et al. 2008; Miller et al. 2005; Solano et al.
2000). However, cell-culture evidence indicates that rat and
mouse oligodendrocytes express asyn protein and mRNA,
and in some cases this expression is transient, appearing in
precursor cells and declining as they mature (Culvenor et al.
2002; Nielsen et al. 2006; Richter-Landsberg et al. 2000). To
date, there is one published study addressing the question of
SNCA mRNA expression in MSA oligodendrocytes (Miller
et al. 2005). This study used double-labeling in situ hybrid-
ization of SNCA and proteolipid protein (PLP), an oligoden-
drocyte marker, and showed that SNCA is not expressed in
oligodendrocytes in MSA or control brains. As ISH has lim-
ited sensitivity, the findings of this study do not exclude the
possibility of SNCA mRNA expression by oligodendrocytes
(Deglincerti and Jaffrey 2012; Miller et al. 2005).
Analyzing SNCA expression in LCM-isolated neurons
and oligodendrocytes, our data indicate that this highly con-
served protein is expressed in human oligodendrocytes and
that expression in MSA oligodendrocytes is greater than con-
trol oligodendrocytes. In our hands, LCM isolation of OSP-
positive oligodendrocytes provides an oligodendrocyte-
enriched sample (Waller et al. 2012). This suggests that
SNCA overexpression in MSA oligodendrocytes may be a
possible mechanism contributing to GCI formation. The
cellular expression of asyn in MSA in this study may also
explain the pathological profile of the disease. GCIs are
found in greater abundance than NCIs in MSA, and this
greater susceptibility of oligodendrocytes to inclusion forma-
tion may be a reflection of overexpression of asyn by oligo-
dendrocytes in MSA.
The novel findings of this LCM study demonstrating
expression of SNCA mRNA in oligodendrocytes open the
door to further exploration of the molecular pathogenesis of
MSA. Expanding the current study to examine cellular
SNCA mRNA expression in other affected and unaffected
brain regions in MSA may help to elucidate the selective
vulnerability of StrN and OPC regions. In addition to
affected and unaffected brain regions, examination of SNCA
expression in MSA cases with short disease duration and
long disease duration may provide further insight into the
role of SNCA mRNA expression on clinical outcome. A fur-
ther step would be to characterize SNCA mRNA expressionT
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in oligodendrocytes with and without GCIs to determine
the contribution of SNCA expression to inclusion formation
in oligodendrocytes. In addition to GCI1/2 oligodendro-
cytes, SNCA mRNA expression may also be explored at dif-
ferent stages of oligodendrocyte maturation. The
oligodendrocyte lineage comprises precursor, immature,
mature nonmyelinating, and mature myelinating cells and
asyn protein in GCIs has been found in mature but not pre-
cursor oligodendrocytes in MSA (Ahmed et al. 2013; Papp
et al. 1989). Therefore, determining SNCA mRNA expres-
sion in the different maturational stages may provide further
insight into the vulnerability of mature oligodendrocytes to
asyn aggregation.
FIGURE 1: SNCA mRNA regional expression (A) Expression
between the different cases (adjusted for regions) shows no stat-
istically significant differences between the groups although the
lowest level of expression was found in MSA-SND and the high-
est in IPD cases (P 5 0.14). (B) After adjusting for case type, a
statistically significant difference in SNCA expression between
regions was found (P < 0.0001), with the lowest expression in
the dorsal putamen and the highest in the occipital cortex. Multi-
level model test with significance level set at P50.05. The box-
plot show median values as the line within the box, the box
reflects the interquartile range and the whiskers the range of the
values.PFR: posterior frontal region; OR: occipital region; Put-D:
dorsal putamen; CBM: cerebellum; Ctx: cortex; WM: white mat-
ter; MSA: multiple system atrophy; SND: striatonigral degenera-
tion; OPC: olivopontocerebellar; IPD: idiopathic Parkinson’s
disease; SNCA: a-synuclein.
FIGURE 2: SNCA mRNA cellular expression(A) SNCA is
expressed in neurons and oligodendrocytes of both MSA and
control cases. Expression in neurons is greater in controls as
compared to MSA (P 5 0.47), in contrast to oligodendrocytes
where expression is greater in MSA (P 5 0.18) but these results
did not reach statistical significance. (B) Bar graph representing
fold change of expression values between the different cases
and cell types. No statistically significant differences were found
although there was a trend toward increased expression in MSA
oligodendrocytes when compared to control oligodendrocytes (P
5 0.18), MSA neurons (P 5 0.16) and control neurons (P 5 0.18).
In contrast, there was a slight decrease in asyn expression in
MSA neurons as compared to control neurons (P 5 0.46). The
greatest difference seems to be the increase in expression in
MSA oligodendrocytes compared with MSA neurons. Mann–
Whitney U test with significance level set at P50.05. The box-
plot shows median values as the line within the box, the box
reflects the interquartile range and the whiskers the range of the
values. Oligo: oligodendrocytes; MSA: multiple system atrophy;
SNCA: a-synuclein.
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